Drugs for Microscopic Colitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 33)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Colestipol |
Approved |
Phase 4 |
|
26658-42-4 |
|
Synonyms:
|
Copolymer of bis(2-aminoethyl)amine and 2-(chloromethyl)oxirane
Epichlorohydrin-tetraethylenepentamine polymer
|
|
2 |
|
Hypolipidemic Agents |
|
Phase 4 |
|
|
|
3 |
|
Lipid Regulating Agents |
|
Phase 4 |
|
|
|
4 |
|
Colesevelam Hydrochloride |
|
Phase 4 |
|
|
|
5 |
|
Anticholesteremic Agents |
|
Phase 4 |
|
|
|
6 |
|
Cholestyramine Resin |
|
Phase 4 |
|
|
|
7 |
|
Antimetabolites |
|
Phase 4 |
|
|
|
8 |
|
Bile Acids and Salts |
|
Phase 4 |
|
|
|
9 |
|
Rifaximin |
Approved, Investigational |
Phase 3 |
|
80621-81-4 |
6436173 46783403 |
Synonyms:
(2S,16Z,18E,20S,21S,22R,23R,24R,25S,26S,27S,28E)-5,6,21,23,25 Pentahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-2,7-(epoxypentadeca(1,11,13)trienimino)benzofuro(4,5-e)pyrido(1,2-a)benzimidazole-1,15(2H)-dione, 25-acetate
4-deoxy-4'-methylpyrido(1',2'-1,2)imidazo(5,4C)rifamycin
4-Deoxy-4'-methylpyrido(1',2'-1,2)imidazo(5,4C)rifamycin
4-Deoxy-4'-methylpyrido(1',2'-1,2)imidazo(5,4-c)rifamycin SV
80621-81-4
88747-56-2
AC-19112
alpha-0817185
Bio-0556
BRN 3584528
C43H51N3O11
CHEMBL1617
D02554
DB01220
Fatroximin
Flonorm
L 105
L 105 (Ansamacrolide antibiotic)
L 105SV
Lormyx
LS-178059
LS-64147
Lumenax
MLS000759430
Normix
Redactiv
|
RedActiv
Rifacol
Rifamixin
Rifamycin L 105
Rifamycin L 105SV
Rifaxidin
Rifaximin
Rifaximin (USAN/INN)
Rifaximin [USAN:INN]
Rifaximina
Rifaximina [Spanish]
Rifaximine
Rifaximine [French]
Rifaximinum
Rifaximinum [Latin]
Rifaximinun
Rifaxin
Ritacol
S1790_Selleck
SMR000466324
Spiraxin
UNII-L36O5T016N
Xifaxan
Xifaxan, Rifacol, Fatroximin, Rifaximin
Xifaxsan
Xifaxsan (TN)
|
|
10 |
|
Budesonide |
Approved |
Phase 2, Phase 3 |
|
51333-22-3 |
63006 5281004 |
Synonyms:
(11b,16a)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(11beta,16alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(11-beta,16-alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(11β,16α)-16,17-(butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(11β,16α)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
(4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
(R,S)-11b,16a,17,21,tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with buty raldehyde
(RS)-(11beta,16alpha)-16,17-[Butylidenebis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione
(RS)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde
(S)-16alpha,17-(Butylidenedioxy)-11beta,21-dihydroxypregna-1,4-diene-3,20-dione
11beta,21-dihydroxy-16alpha,17alpha-(butane-1,1-diyldioxy)pregna-1,4-diene-3,20-dione
16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione
16,17-Butylidenebis(oxy)-11-,21-dihydroxypregna-1,4-diene-3,20-dione
16alpha(R),17-(Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione
16-alpha,17-alpha-Butylidenedioxy-11-beta,21-dihydroxy-1,4-pregnadiene-3,20-dione
16alpha-,17alpha--butylidenedioxypregna-1,4-diene-11beta-,21-diol-3,20-dione
51333-22-3
AC1L1DQE
AC1L1Y6Y
AC1L22VC
AC1MHWI7
AC-4697
B 7777
B7777_SIGMA
Bidien
Bio-0010
BPBio1_000523
BRD-A34299591-001-03-4
BRD-A82238138-001-01-7
BSPBio_000475
BSPBio_002160
Budecort Inhaler
Budenofalk
Budeson
Budesónida
budesonide
Budesonide
Budesonide (JAN/USAN/INN)
Budesonide [USAN:INN:BAN:JAN]
Budesonide Easyhaler
Budesonide MMX
Budesonide, (R)-isomer
Budesonide, (S)-isomer
Budesonido
Budesonido [INN-Spanish]
Budesonidum
Budesonidum [INN-Latin]
Budiair
Budicort
C25H34O6
CCRIS 5230
CHEBI:3207
CHEBI:656601
CHEMBL1370
CID2462
CID3033890
CID40000
CID5281004
CID63006
Cortivent
CPD000058337
D00246
DB01222
Desowen
Dexbudesonide
Dexbudesonide [INN]
DivK1c_000475
EINECS 257-139-7
EINECS 257-160-1
EINECS 257-161-7
Entocort
Entocort EC
Entocort EC (TN)
EU-0100174
Giona Easyhaler
HMS1569H17
|
HMS1921I22
HMS2094I13
HMS501H17
Horacort
IDI1_000475
Inflammide
KBio1_000475
KBio3_001660
KBioGR_001361
Lopac0_000174
LS-187734
LS-7235
MAP-0010
Micronyl
Miflonide
MLS000028507
MLS001077323
MLS002207112
MolPort-002-529-265
MolPort-003-666-332
MolPort-003-986-909
NCGC00015165-03
NCGC00021318-03
NCGC00021318-06
NCGC00089747-02
NCGC00089747-03
NCGC00089747-04
NCGC00178789-01
NINDS_000475
Noex
Preferid
Pregna-1,4-diene-3,20-dione, 16,17-butylidenebis(oxy)-11,21-dihydroxy-, (11beta,16alpha(R))-, and 16alpha,17-((S)-Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione
Prestwick_840
Prestwick0_000518
Prestwick1_000518
Prestwick2_000518
Prestwick3_000518
Pulmaxan
Pulmaxan turbohaler
Pulmicort
Pulmicort (TN)
Pulmicort Flexhaler
Pulmicort Nebuamp
Pulmicort Respules
Pulmicort Topinasal
Pulmicort turbuhaler
Pulmicort Turbuhaler
Respules
Rhinocort
Rhinocort alpha
Rhinocort Aqua
Rhinocort Turbuhaler
Rhinocort, Pulmicort , Entocort, Symbicort, Noex. Entocort EC, Budesonide
Rhinosol
S 1320
S1286_Selleck
S-1320
SAM002699898
SMR000058337
SPBio_000586
SPBio_002396
SPECTRUM1500813
Spectrum2_000623
Spectrum3_000620
Spectrum4_000821
Spectrum5_001738
Spirocort
ST51039033
TL8003397
Tridesilon
UDB
UNII-168L5HT37P
UNII-2HI1006KPH
UNII-Q3OKS62Q6X
Unit dose budesonide
ZINC03938751
ZINC04097286
|
|
11 |
|
Mesalamine |
|
Phase 2, Phase 3 |
|
89-57-6 |
|
12 |
|
Analgesics, Non-Narcotic |
|
Phase 2, Phase 3 |
|
|
|
13 |
|
Analgesics |
|
Phase 2, Phase 3 |
|
|
|
14 |
|
Antirheumatic Agents |
|
Phase 2, Phase 3 |
|
|
|
15 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 2, Phase 3 |
|
|
|
16 |
|
Gastrointestinal Agents |
|
Phase 3 |
|
|
|
17 |
|
Anti-Bacterial Agents |
|
Phase 3 |
|
|
|
18 |
|
Anti-Infective Agents |
|
Phase 3 |
|
|
|
19 |
|
Respiratory System Agents |
|
Phase 2, Phase 3 |
|
|
|
20 |
|
Hormones |
|
Phase 2, Phase 3 |
|
|
|
21 |
|
Anti-Asthmatic Agents |
|
Phase 2, Phase 3 |
|
|
|
22 |
|
Hormone Antagonists |
|
Phase 2, Phase 3 |
|
|
|
23 |
|
glucocorticoids |
|
Phase 2, Phase 3 |
|
|
|
24 |
|
Bronchodilator Agents |
|
Phase 2, Phase 3 |
|
|
|
25 |
|
Anti-Inflammatory Agents |
|
Phase 2, Phase 3 |
|
|
|
26 |
|
Pharmaceutical Solutions |
|
|
|
|
|
27 |
|
Cola |
|
|
|
|
|
28 |
|
Immunoglobulins |
|
|
|
|
|
29 |
|
Antibodies |
|
|
|
|
|
30 |
|
Antacids |
|
|
|
|
|
31 |
|
Anti-Ulcer Agents |
|
|
|
|
|
32 |
|
Bismuth |
|
|
|
7440-69-9 |
16682734 105143 |
Synonyms:
17034_FLUKA
24267-48-9
25243-76-9
264008_ALDRICH
265462_ALDRICH
265470_ALDRICH
452386_ALDRICH
556130_ALDRICH
7440-69-9
83Bi
95372_ALDRICH
95372_FLUKA
95375_FLUKA
AC1NSDYX
AC1O4PN8
AR-1I0647
Bi
Bi(3+)
Bismut
bismuth
|
Bismuth standard for AAS
Bismuth standard for ICP
Bismuth(III) cation
Bismuth(III) nitrate solution
BISMUTH, 99.95%
BISMUTH, 99.999%
Bismuth, elemental
Bismuth-209
bismuto
Bisumth(3+) ion
C15471
CHEBI:33301
CID5359367
EINECS 231-177-4
HSDB 2078
LS-44708
LTBB002773
MolPort-003-925-759
Wismut
|
|
33 |
|
Serotonin |
Investigational, Nutraceutical |
|
|
50-67-9 |
5202 |
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5 Hydroxytryptamine
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
5-Hydroxy-tryptamine
Antemovis
|
DS Substance
Enteramin
Enteramine
Hippophaine
Hydroxytryptamine
Serotonine
sérotonine
thrombocytin
Thrombocytin
thrombotonin
Thrombotonin
|
|
Interventional clinical trials:
(show all 23)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Treatment Effect of Colesevelam for Bile Acid Diarrhoea - a Randomised Placebo-controlled Trial |
Recruiting |
NCT03876717 |
Phase 4 |
Colesevelam Hydrochloride;Placebo oral capsule |
2 |
Efficacy and Safety of Budesonide for Treatment of Lymphocytic Colitis |
Completed |
NCT00180050 |
Phase 3 |
Budesonide |
3 |
Efficacy and Safety of Budesonide in Maintenance Treatment of Collagenous Colitis |
Completed |
NCT00180076 |
Phase 3 |
Budesonide |
4 |
A Randomized, Dose Ranging Trial of Mesalmine for the Treatment of Active Microscopic Colitis. |
Completed |
NCT00952952 |
Phase 2, Phase 3 |
Mesalamine |
5 |
Effect of Mesalazine on Low Grade Mucosal Inflammation in Irritable Bowel Syndrome. A Pilot Double Blind Placebo Controlled Study. |
Completed |
NCT00774007 |
Phase 2, Phase 3 |
mesalazine;placebo |
6 |
Randomised, Double-blind, Placebo-controlled, Multi-centre Trial on the Efficacy and Safety of Budesonide for Induction of Remission in Incomplete Microscopic Colitis |
Active, not recruiting |
NCT02142634 |
Phase 3 |
Budesonide granules 9 mg;Placebo granules |
7 |
Rifaximin-treatment of Collagenous Colitis: |
Not yet recruiting |
NCT03658993 |
Phase 3 |
Rifaximin 550 MG |
8 |
A Randomized, Double-Blind, Placebo Controlled Trial of Budesonide for the Treatment of Active Lymphocytic Colitis |
Terminated |
NCT00217022 |
Phase 2, Phase 3 |
Budesonide |
9 |
Efficacy and Safety of Oral Rifaximin in Patients With Active Microscopic Colitis |
Recruiting |
NCT04043897 |
Phase 2 |
Rifaximin 550mg |
10 |
Prospective Study on the Usefulness of Chromoendoscopy in Detecting Microscopic Colitis in Patients Undergoing Colonoscopy Due to Chronic Watery Diarrhoea |
Unknown status |
NCT01504048 |
|
|
11 |
Microbe-Gut Interaction in Microscopic Colitis and Post-Infectious Irritable Bowel Syndrome (IBS) |
Unknown status |
NCT01787253 |
|
|
12 |
Risk Factors for Microscopic Colitis: A Dutch Case-Control Study |
Completed |
NCT01928667 |
|
|
13 |
Ex Vivo Experiments to Evaluate the Role of Medication on the Colon Permeability in Microscopic Colitis |
Completed |
NCT02303132 |
|
|
14 |
Faecal Microbiota Transplantation in Patients With Microscopic Colitis |
Completed |
NCT03275467 |
|
|
15 |
Effects of Faecal Microbiota Transplantation in Patients With Irritable Bowel Syndrome: A Randomised, Double-blind Placebo-controlled Study |
Completed |
NCT03822299 |
|
|
16 |
Faecal Transplantation in Inflammatory Bowel Disease |
Recruiting |
NCT03477032 |
|
|
17 |
Risk Factors for Microscopic Colitis |
Recruiting |
NCT02699333 |
|
|
18 |
Identification and Characterization of Microbial and Immunologic Changes in Microscopic Colitis |
Recruiting |
NCT03063957 |
|
|
19 |
Interest of Pan Capsule (Small Bowel and Colon Video Capsule) in Symptomatic Patients Suspected of Irritable Bowel Syndrome Requiring Colonoscopy. Phase A. Feasibility |
Recruiting |
NCT03806959 |
|
|
20 |
Fecal Microbiota Transplantation for the Treatment of Recurrent or Refractory Clostridium Difficile Infection (CDI) |
Recruiting |
NCT01905709 |
|
|
21 |
Investigating Serotonin Signalling in IBD Patients |
Recruiting |
NCT01650311 |
|
|
22 |
Early Detection of Tumors of the Digestive Tract by Confocal Endomicroscopy |
Recruiting |
NCT02284802 |
|
|
23 |
Treatment of Microscopic Colitis (Collagenous Colitis and Lymphocytic Colitis) With Budesonide, Bismuth or Fiber |
Terminated |
NCT00184171 |
|
Budesonide;Bismuth;Fiber |
|